Patients and the public experienced rapid availability of new vaccines and treatments against COVID-19 infections during the pandemic in 2020. Although it is obvious that this was due to exceptional circumstances, it has raised the expectations for shorter development times for future medicines. Therefore, time pressure on clinical researchers and regulators has further increased and calls for innovation and creativity. In the EUFEMED 2023 conference we will discuss options and strategies for Mastering the New Time Pressure on Human Pharmacology in order to achieve shorter timelines in early medicines development.

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event